COIOSDeep risk insights through multi-disciplinary research across the globe
buildings with lights on
Item refines Peer-reviewed Added

Proteomic organ clocks tracked 16-year mortality less closely than epigenetic age

Accelerated liver, immune and heart proteomic ageing carried hazard ratios of 1.38 to 1.43 per standard deviation for 16-year mortality, below those for epigenetic age and cognition.

Plasma proteomic organ clocks were compared with other ageing biomarkers in 861 members of the Lothian Birth Cohort 1936, of whom 444 died. Accelerated liver, immune and heart ageing carried hazard ratios of 1.38 to 1.43 per standard deviation. Epigenetic age, brain volume, respiratory function and cognition were more strongly associated, at 1.44 to 1.62.

Why it is interesting: The newer proteomic organ clocks were the weaker predictors of death in this cohort.

Source
Aging Cell, 1 October 2026
Paper
Multimodal Ageing Biomarkers and Plasma Proteomic Signatures Associated With All-Cause Mortality
Authors
Pyrgioti M, Eguiagaray IM, Redmond P, Corley J, Bastin ME, Hernández MV et al.
DOI
10.1111/acel.70747
Type
Peer-reviewed article
Design
Prospective cohort, Lothian Birth Cohort 1936, 861 participants, 444 deaths over 16 years; Cox regression benchmarking of ageing biomarkers and 9703 plasma protein targets
Verdict
Refines prior evidence
Driver
Slowing ageing itself
Driver
Frailty and multimorbidity
Free full text
Free to read at the publisher
Abstract — the authors' own words, CC BY

Ageing biomarkers quantify molecular, physiological or functional features that vary between individuals as they age and may improve prediction of health outcomes beyond chronological age. Recently, plasma proteomics have been used to estimate the biological ages of 11 human organs. Although accelerated organ ageing is associated with higher mortality risk, systematic benchmarking against established ageing biomarkers is lacking. Here, we pursued two complementary aims. First, we benchmarked proteomic organ clocks against multimodal ageing biomarkers for associations with 16-year all-cause mortality in the Lothian Birth Cohort 1936 (LBC1936) using Cox regression (861 participants; 444 deaths). Biomarkers included the epigenetic clock GrimAge2, telomere length, physical function (grip strength, walk time and respiratory function), neuroimaging and cognitive measures. Among proteomic clocks, accelerated liver (HR perSD [95% CI] = 1.43 [1.30-1.58]), immune (1.42 [1.29-1.57]) and heart (1.38 [1.25-1.53]) ageing were most strongly associated with increased mortality risk. However, older epigenetic age, smaller total brain and grey matter volumes, reduced respiratory function and poorer cognition showed stronger associations with mortality (HR perSD = 1.44-1.62). Second, survival analyses of 9703 plasma protein targets identified 368 candidates associated with mortality, with high-risk proteins enriched for immune functions, and low-risk proteins involved in genomic stability and cellular maintenance. GDF15 (HR perSD [95% CI] = 1.56 [1.42-1.72]), WFDC2 (1.47 [1.33-1.62]) and TIMP1 (1.45 [1.29-1.62]) were the leading proteomic candidates associated with mortality. This study provides a systematic, cross-modal benchmarking of proteomic organ clocks against established ageing biomarkers and identifies proteins and biological functions associated with mortality risk.

Other drivers in Tomorrow's world